Jedd F. Levine

Oncology

19 W Main St
Sharon, CT 06069

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications.

Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications.

Journal: Cancers

Published: April 03, 2023

Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.

Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.

Journal: Molecular cancer therapeutics

Published: November 22, 2022

Corrigendum to "1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents" [Bioorg. Med. Chem. Lett. 27 (2017) 4471-4477].

Corrigendum to "1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents" [Bioorg. Med. Chem. Lett. 27 (2017) 4471-4477].

Journal: Bioorganic & medicinal chemistry letters

Published: February 13, 2018

1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents.

1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents.

Journal: Bioorganic & medicinal chemistry letters

Published: June 20, 2017

Showing 1-4 of 4

Last Updated: 09/26/2026